Novartis has reported positive results from a late-stage clinical trial showing that its monoclonal antibody erenumab provided relief to patients with migraine who have been unsuccessful in treating their disease with two to four other therapies. ---Subscribe to MedNous to access this article--- Clinical Research Company News
